| |
All patientsN=226 |
Normal diastolic functionN=135 |
Grade I diastolic dysfunctionN=82 |
Grade ≥2 diastolic dysfunctionN=9 |
P value |
| Demographics |
|
|
|
|
|
| Age, years |
49.5±14.3 |
42.7±12.2 |
59.6±11.0 |
59±10 |
<0.0001 |
| Female gender |
177(78.3%) |
104(77.0%) |
67(82.6%) |
6(66.7%) |
0.50 |
| Nationality |
|
|
|
|
0.014 |
| Lebanese |
167(73.8%) |
90(66.7%) |
72(87.8%) |
5(55.6%) |
|
| Iraqi |
51(22.6%) |
40(29.6%) |
8(9.8%) |
3(33.3%) |
|
| Others |
8(3.5%) |
5(3.7%) |
2(2.4%) |
1(11.1%) |
|
| Body mass index, kg/m2 (n=222) |
27.3±5.2 |
26.9±5.3 |
28.1±4.9 |
25.6±4.6 |
0.16 |
| Body surface area, m2 (n=222) |
1.8±0.2 |
1.8±0.2 |
1.8±0.1 |
1.7±0.2 |
0.11 |
| Comorbidities |
|
|
|
|
|
| Systolic blood pressure, mmHg (n=208) |
127±17 |
123±15 |
133±17 |
136±22 |
<0.0001 |
| Hypertension |
57(25.2%) |
22(16.3%) |
29(35.3%) |
6(66.7%) |
<0.0001 |
| Diabetes |
20(8.8%) |
7 (5.2%) |
11 (13.4%) |
2 (22.2%) |
0.042 |
| Prior revascularization |
17(7.6%) |
5 (3.7%) |
11 (13.4%) |
1 (11.1%) |
0.030 |
| Smoking history |
81(35.8%) |
44(32.6%) |
34(41.5%) |
3(33.3%) |
0.43 |
| Sedentary lifestyle |
190(84.0%) |
109(80.7%) |
74(90.2%) |
7 (77.8%) |
0.12 |
| Cancer type |
|
|
|
|
0.17 |
| Breast cancer |
147(65.0%) |
87(64.4%) |
55(67.1%) |
5(55.6%) |
|
| Lymphoma |
27 (11.9%) |
19 (14.1%) |
7(8.5%) |
1(11.1%) |
|
| Other |
52(23.0%) |
29(21.5%) |
20(24.4%) |
3(33.3%) |
|
| Creatinine, mg/dl (n=202) |
0.74±0.4 |
0.70±0.2 |
0.75±0.2 |
1.24±1.4 |
<0.0001 |
| Glomerular filtration rate, ml/min/1.72m2 (n=194) |
130±47 |
144±46 |
115±39 |
73±45 |
<0.0001 |
| Medications |
|
|
|
|
|
| Beta blockers |
48(21.2%) |
15(11.1%) |
29(35.4%) |
4(44.4%) |
<0.0001 |
| ACEi/ARB |
40 (17.7%) |
15(11.1%) |
21(25.6%) |
4(44.4%) |
0.003 |
| Statins |
35(15.5%) |
12 (8.9%) |
21 (25.6%) |
2 (22.2%) |
0.004 |
| Anthracyclines or monoclonal antibodies based tyrosine kinase inhibitors |
49(21.7%) |
33(24.4%) |
15(18.3%) |
1(11.1%) |
0.42 |
| Echocardiographic parameters |
|
|
|
|
|
| LVEDd/height, mm/m (n=221) |
28±3 |
28±4 |
27±3 |
29±4 |
0.22 |
| LVESd/height, mm/m (n=220) |
18±2 |
19±2 |
18±2 |
19±3 |
0.47 |
| LV mass index, g/m2 (n=212) |
46±12 |
43±9 |
49±12 |
61±24 |
<0.0001 |
| Ejection fraction, % |
59.8±3.9 |
59.6±3.8 |
60.2±4.2 |
59.8±2.6 |
0.54 |
| Global longitudinal strain, % (n=87) |
-19.8±2.3 |
-20±2.3 |
-19.4±2.3 |
-19.2±1.9 |
0.54 |
| LA volume index, ml/m2 (n=216) |
23±5 |
22±5 |
24±6 |
34±3 |
<0.0001 |
| E, cm/s |
74±18 |
81±17 |
63±13 |
83±18 |
<0.0001 |
| A, cm/s |
72±19 |
65±16 |
83±17 |
68±18 |
<0.0001 |
| E/A |
1.14±0.70 |
1.38±0.82 |
0.76±0.10 |
1.25±0.26 |
<0.0001 |
| Deceleration time, ms |
205±35 |
185±23 |
238±27 |
184±24 |
<0.0001 |
| e’ lateral, cm/s |
11.4±3.4 |
13.2±3.0 |
8.3±1.5 |
8.4±1.1 |
<0.0001 |
| E/e’ |
7.04±2.29 |
6.4±1.9 |
7.8±2.2 |
10±3.9 |
<0.0001 |
| TAPSE, mm (n=172) |
23±12 |
22±4 |
24±19 |
23±4 |
0.70 |
| Right ventricular S’, cm/s (n=198) |
14±3 |
14±3 |
14±4 |
14±3 |
0.76 |
| Systolic PAP, mmHg (n=111) |
28±6 |
28±6 |
28±5 |
32±6 |
0.10 |
